Noul Co

Noul Co EBITDA per Share

The EBITDA per Share of Noul Co (376930.KQ) as of Oct 30, 2026 is -503.31 KRW. In the previous year, EBITDA per Share was -576.34 KRW — a change of -12.67% (higher).

EBITDA per Share

-503.31KRW

YoY

-12.67%

Last updated:

EBITDA per Share of Noul Co is 2025 -503.31 KRW. EBITDA per Share of Noul Co was 2024 -576.34 KRW. It decreases by -12.67% higher compared to the previous year.

The Noul Co EBITDA per Share history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA per Share
Date
EBITDA per Share
Jan 1, 2019
-444.35 KRW
Jan 1, 2020
-366.32 KRW
Jan 1, 2021
-516.26 KRW
Jan 1, 2022
-645.03 KRW
Jan 1, 2023
-409.85 KRW
Jan 1, 2024
-576.34 KRW
Jan 1, 2025
-503.31 KRW
The Noul Co EBITDA per Share history
YEAREBITDA per ShareYoY
-503.31KRW-12.67%
-576.34KRW+40.62%
-409.85KRW-36.46%
-645.03KRW+24.94%
-516.26KRW+40.93%
-366.32KRW-17.56%
-444.35KRW—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Noul Co Stock analysis

What does Noul Co do? Noul Co., Ltd. generates revenue through the manufacture and sale of blood test diagnostic devices utilizing AI algorithms and diagnostic kits. The company offers regular monthly subscriptions via its integrated web-based remote diagnosis system, targeting healthcare providers and medical facilities seeking advanced diagnostic solutions. Its core products include AI-based diagnostic devices and associated kits, sold directly to clinics and hospitals for use in blood testing procedures. The firm's services are designed to enhance diagnostic accuracy and efficiency through remote access and subscription models. The company's primary revenue streams stem from the sale of physical diagnostic devices and diagnostic kits, alongside recurring subscription fees for its web-based remote diagnosis platform. Healthcare institutions and medical professionals form the key customer segments, purchasing both the hardware and ongoing service access. Noul Co., Ltd. focuses on delivering AI-driven diagnostic tools that integrate seamlessly into existing healthcare workflows, emphasizing convenience and technological innovation for its clients. Noul Co., Ltd. operates exclusively within the healthcare diagnostics sector, providing AI-powered blood test solutions that combine hardware sales with subscription-based software services. The business model relies on initial device purchases followed by continuous revenue from monthly subscriptions, creating a sustainable income stream. This approach ensures long-term engagement with healthcare providers while maintaining a focus on cutting-edge diagnostic technology. Noul Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Noul Co stock

EBITDA per Share of Noul Co is -503.31 KRW in 2025.

EBITDA per Share of Noul Co changed from -576.34 KRW to -503.31 KRW, representing a -12.67% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of EBITDA per Share Noul Co since 2006 – with annual values, charts, and detailed analysis.

EBITDA per share divides EBITDA by shares outstanding, showing the operating cash earnings allocated to each share before depreciation and financing effects.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Income Statement — Noul Co

All Key Metrics — Noul Co